Florian Muller, Chief Scientific Officer at Lindonlight Collective, shared on LinkedIn:
“A nice example of an actual clinical trial of an ADC with a non-cytotoxic payload. 20% ORR isn’t going to get too much news, but it is a nice demonstration of what is possible.
Some salient points:
- Very high dosing (24 mg/kg Q2W!)
- An exceptionally high-expressed surface target (PMEL)
- A relatively high ratio of free payload to intact ADC.”
Title: An anti-PMEL antibody−drug conjugate with a Gq/11 inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial
Authors: Matteo S. Carlino, Ellen Kapiteijn, Sophie Piperno-Neumann, Ryan J. Sullivan, Richard Carvajal, Reinhard Dummer, Tanja Gromke, Jessica C. Hassel, Damien Kee, Egle Ramelyte, Alexander N. Shoushtari, Alexander Z. Wei, Alexander Enk, Eleanor E. Handel, Kamaneh Montazeri, Jorge Ramon-Patino, Heike Richly, Manuel Rodrigues, Shahneen Sandhu, James Smithy, Frank M. Speetjens, Pedro Milanez-Almeida, Anwesha Chaudhury, Keith Hoffmaster, Mary Ising, Javier A. Otero, Thiruvamoor RamKumar, Aimee Reynolds, Sherif Sharaby, Lillian Werner, Padmaja Yerramilli-Rao, Emiliano Calvo
Other articles about Melanoma on OncoDaily.